Strategy for marginally resectable lung cancer

Masahiro Kaji, Rei Kobayashi, Yumi Hino, Kyohei Masai, Naofumi Miyahara, Fumio Sakamaki, Keisuke Miyamoto, Hirofumi Kamata, Daisuke Taniyama, Keiichi Suemasu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Lung cancer accounts for the largest number of new cases of cancer deaths annually. The treatment of locally advanced non-small-cell lung cancer (NSCLC) will continue to be a problem for many years. In particular, the border-zone subset of stage III A (N2) patients, which lies between the generally resectable stage I and II tumors and the unresectable stage III B patients, has been the subject of a wide variety of clinical trials incorporating various combinations of chemotherapy, radiotherapy, and surgery. "What is the ideal therapy for stage III A (N2) patients?" is a controversial question, and the role of surgery is not clearly defined because of its heterogeneous nature. Most importantly, treatment decisions for these patients should be dictated by the stage of the patients' disease and the patients' performance status, medical comorbidities, and preferences. At our hospital, therefore, all of these patients' data are discussed at our cancer-board conference, incorporating the options of thoracic surgeons, medical oncologists, and radiation oncologists to determine the optimal prospective treatment strategies for the patients. We focused on a treatment strategy for the patients with the so called 'marginally resectable' lung cancer in this article.

Original languageEnglish
Pages (from-to)1256-1260
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume38
Issue number8
Publication statusPublished - 2011
Externally publishedYes

Fingerprint

Lung Neoplasms
Therapeutics
Neoplasms
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Comorbidity
Radiotherapy
Thorax
Clinical Trials

Keywords

  • Lung cancer
  • Marginally resectable tumor
  • Multimodality treatment
  • N2 disease

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Kaji, M., Kobayashi, R., Hino, Y., Masai, K., Miyahara, N., Sakamaki, F., ... Suemasu, K. (2011). Strategy for marginally resectable lung cancer. Japanese Journal of Cancer and Chemotherapy, 38(8), 1256-1260.

Strategy for marginally resectable lung cancer. / Kaji, Masahiro; Kobayashi, Rei; Hino, Yumi; Masai, Kyohei; Miyahara, Naofumi; Sakamaki, Fumio; Miyamoto, Keisuke; Kamata, Hirofumi; Taniyama, Daisuke; Suemasu, Keiichi.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 38, No. 8, 2011, p. 1256-1260.

Research output: Contribution to journalArticle

Kaji, M, Kobayashi, R, Hino, Y, Masai, K, Miyahara, N, Sakamaki, F, Miyamoto, K, Kamata, H, Taniyama, D & Suemasu, K 2011, 'Strategy for marginally resectable lung cancer', Japanese Journal of Cancer and Chemotherapy, vol. 38, no. 8, pp. 1256-1260.
Kaji M, Kobayashi R, Hino Y, Masai K, Miyahara N, Sakamaki F et al. Strategy for marginally resectable lung cancer. Japanese Journal of Cancer and Chemotherapy. 2011;38(8):1256-1260.
Kaji, Masahiro ; Kobayashi, Rei ; Hino, Yumi ; Masai, Kyohei ; Miyahara, Naofumi ; Sakamaki, Fumio ; Miyamoto, Keisuke ; Kamata, Hirofumi ; Taniyama, Daisuke ; Suemasu, Keiichi. / Strategy for marginally resectable lung cancer. In: Japanese Journal of Cancer and Chemotherapy. 2011 ; Vol. 38, No. 8. pp. 1256-1260.
@article{c6dfc9582a674bf38f21e09e2f16b3c0,
title = "Strategy for marginally resectable lung cancer",
abstract = "Lung cancer accounts for the largest number of new cases of cancer deaths annually. The treatment of locally advanced non-small-cell lung cancer (NSCLC) will continue to be a problem for many years. In particular, the border-zone subset of stage III A (N2) patients, which lies between the generally resectable stage I and II tumors and the unresectable stage III B patients, has been the subject of a wide variety of clinical trials incorporating various combinations of chemotherapy, radiotherapy, and surgery. {"}What is the ideal therapy for stage III A (N2) patients?{"} is a controversial question, and the role of surgery is not clearly defined because of its heterogeneous nature. Most importantly, treatment decisions for these patients should be dictated by the stage of the patients' disease and the patients' performance status, medical comorbidities, and preferences. At our hospital, therefore, all of these patients' data are discussed at our cancer-board conference, incorporating the options of thoracic surgeons, medical oncologists, and radiation oncologists to determine the optimal prospective treatment strategies for the patients. We focused on a treatment strategy for the patients with the so called 'marginally resectable' lung cancer in this article.",
keywords = "Lung cancer, Marginally resectable tumor, Multimodality treatment, N2 disease",
author = "Masahiro Kaji and Rei Kobayashi and Yumi Hino and Kyohei Masai and Naofumi Miyahara and Fumio Sakamaki and Keisuke Miyamoto and Hirofumi Kamata and Daisuke Taniyama and Keiichi Suemasu",
year = "2011",
language = "English",
volume = "38",
pages = "1256--1260",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "8",

}

TY - JOUR

T1 - Strategy for marginally resectable lung cancer

AU - Kaji, Masahiro

AU - Kobayashi, Rei

AU - Hino, Yumi

AU - Masai, Kyohei

AU - Miyahara, Naofumi

AU - Sakamaki, Fumio

AU - Miyamoto, Keisuke

AU - Kamata, Hirofumi

AU - Taniyama, Daisuke

AU - Suemasu, Keiichi

PY - 2011

Y1 - 2011

N2 - Lung cancer accounts for the largest number of new cases of cancer deaths annually. The treatment of locally advanced non-small-cell lung cancer (NSCLC) will continue to be a problem for many years. In particular, the border-zone subset of stage III A (N2) patients, which lies between the generally resectable stage I and II tumors and the unresectable stage III B patients, has been the subject of a wide variety of clinical trials incorporating various combinations of chemotherapy, radiotherapy, and surgery. "What is the ideal therapy for stage III A (N2) patients?" is a controversial question, and the role of surgery is not clearly defined because of its heterogeneous nature. Most importantly, treatment decisions for these patients should be dictated by the stage of the patients' disease and the patients' performance status, medical comorbidities, and preferences. At our hospital, therefore, all of these patients' data are discussed at our cancer-board conference, incorporating the options of thoracic surgeons, medical oncologists, and radiation oncologists to determine the optimal prospective treatment strategies for the patients. We focused on a treatment strategy for the patients with the so called 'marginally resectable' lung cancer in this article.

AB - Lung cancer accounts for the largest number of new cases of cancer deaths annually. The treatment of locally advanced non-small-cell lung cancer (NSCLC) will continue to be a problem for many years. In particular, the border-zone subset of stage III A (N2) patients, which lies between the generally resectable stage I and II tumors and the unresectable stage III B patients, has been the subject of a wide variety of clinical trials incorporating various combinations of chemotherapy, radiotherapy, and surgery. "What is the ideal therapy for stage III A (N2) patients?" is a controversial question, and the role of surgery is not clearly defined because of its heterogeneous nature. Most importantly, treatment decisions for these patients should be dictated by the stage of the patients' disease and the patients' performance status, medical comorbidities, and preferences. At our hospital, therefore, all of these patients' data are discussed at our cancer-board conference, incorporating the options of thoracic surgeons, medical oncologists, and radiation oncologists to determine the optimal prospective treatment strategies for the patients. We focused on a treatment strategy for the patients with the so called 'marginally resectable' lung cancer in this article.

KW - Lung cancer

KW - Marginally resectable tumor

KW - Multimodality treatment

KW - N2 disease

UR - http://www.scopus.com/inward/record.url?scp=80054760998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054760998&partnerID=8YFLogxK

M3 - Article

C2 - 21829062

AN - SCOPUS:80054760998

VL - 38

SP - 1256

EP - 1260

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 8

ER -